P
6.72
0.13 (1.97%)
| Previous Close | 6.59 |
| Open | 6.66 |
| Volume | 1,986,893 |
| Avg. Volume (3M) | 1,415,286 |
| Market Cap | 703,125,888 |
| Price / Sales | 9.32 |
| Price / Book | 2.91 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | -98.10% |
| Operating Margin (TTM) | -85.88% |
| Diluted EPS (TTM) | -1.29 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Total Debt/Equity (MRQ) | 21.81% |
| Current Ratio (MRQ) | 6.91 |
| Operating Cash Flow (TTM) | -42.70 M |
| Levered Free Cash Flow (TTM) | -23.09 M |
| Return on Assets (TTM) | -17.90% |
| Return on Equity (TTM) | -51.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Personalis, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 31.49% |
| % Held by Institutions | 46.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blue Water Life Science Advisors, Lp | 31 Dec 2025 | 1,676,300 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 13.00 (BTIG, 93.45%) | Buy |
| 13.00 (Guggenheim, 93.45%) | Buy | |
| Median | 12.50 (86.01%) | |
| Low | 10.00 (Morgan Stanley, 48.81%) | Hold |
| Average | 12.00 (78.57%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 9.22 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 05 Mar 2026 | 10.00 (48.81%) | Hold | 8.56 |
| Needham | 27 Feb 2026 | 12.00 (78.57%) | Buy | 9.06 |
| BTIG | 11 Feb 2026 | 13.00 (93.45%) | Buy | 8.90 |
| 09 Jan 2026 | 12.00 (78.57%) | Buy | 8.10 | |
| Guggenheim | 26 Jan 2026 | 13.00 (93.45%) | Buy | 10.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors |
| 28 Jan 2026 | Announcement | Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
| 12 Jan 2026 | Announcement | Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ |
| 08 Jan 2026 | Announcement | Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |